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Background: Tamsulosin, an α1-adrenoceptor antagonist, and sildenafil, a phosphodiesterase (PDE) inhibitor, are
reported to improve lower urinary tract symptoms including overactive bladder (OAB). This study is aimed at
investing the effects of tamsulosin and sildenafil and comparing the degree of the suppressive effects on the
afferent pathways of micturition between them using an animal model of OAB, the spontaneously hypertensive
rat (SHR).
Results: The cystometric parameters, the basal pressure and duration of bladder contraction, were significantly
increased in the SHR group as compared with the Wistar-Kyoto (WKY) group. The intercontraction interval also
significantly decreased in the SHR group. In the SHR-Tam 0.01 mg/kg group and the SHR-Sil 1 mg/kg group,
however, the basal pressure and duration were significantly reduced and the intercontraction interval was
significantly prolonged. Moreover, the degree of the expression of c-Fos and NGF was significantly higher in the
SHR group as compared with the WKY group. But it was significantly reduced in the SHR-Tam 0.01 mg/kg group
and the SHR-Sil 1 mg/kg group. Furthermore, tamsulosin had a higher degree of effect as compared with sildenafil.
Conclusions: In conclusion, α1-adrenergic receptor antagonists and PDE-5 inhibitors may have an effect in improving
the voiding functions through an inhibition of the neuronal activity in the afferent pathways of micturition.
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Overactive bladder (OAB) syndrome is clinically diagnosed
based on the presence of urinary urgency [1]. In addition,
its symptoms significantly have a negative impact on the
emotional well-being and work productivity of affected
individuals [2]. Still, however, little is known about its
underlying pathophysiology [1].
The bladder and external urethral sphincter are inner-
vated directly or indirectly by the nerve fibers arising from
several brain regions including the pontine micturition
center (PMC), hypothalamus and preoptic area [3]. The
PMC regulates the storage and elimination of urine [4].
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reproduction in any medium, provided the orplays a key role in provoking the micturition reflex, and
interneurons in the lumbosacral cord project to the lateral
and dorsal parts of the PAG [5]. The central micturition
regions, such as the PAG and PMC, are activated by
stimulation of the bladder in the OAB group. This in-
creases the expression of c-Fos in the central micturition
regions in the brain as compared with normal controls [6].
c-Fos is an immediate early gene, and its expression is
triggered by stimuli-induced changes in the metabolic
activity of neurons under various conditions [7]. It serves
as an indicator for the neuronal activity [6]. It has also
been proposed not only that nerve growth factor (NGF) is
involved in the neuronal function by which the micturition
pathways are modulated but also that its expression serves
as an indicator for the bladder overactivity [8].
One of the α1-adrenoceptor blockers, tamsulosin is
considered the most effective regimen for patients with. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of benign prostatic hyperplasia [9]. Long-term clinical
studies have shown that storage and voiding symptoms
were improved when used alone or in combination with
other drugs, such as phosphodiesterase-5 (PDE-5) inhib-
itors [9,10]. Therapeutic potentials of PDE-5 inhibitors
including sildenafil for the lower urinary tract dysfunction
including OAB have been suggested [11]. According to
Ückert and Oelke, randomized, placebo-controlled trials
and preliminary open-label studies have addressed the
effectiveness of PDE-5 inhibitors in improving the lower
urinary tract dysfunction [12]. Thus, these authors reported
that it would be a novel approach for the treatment of
patients with lower urinary tract dysfunction to modu-
late the activity of PDE isoenzymes. Of note, sildenafil
was effective in improving the LUTS, including detrusor
overactivity [13].
Although many studies have reported the efficacies of
α1-adrenergic receptor blockers and PDE inhibitors on
storage and voiding symptoms, their exact mechanisms
of action based on the expression of neuronal activity
markers remain unclear [9-13]. Moreover, no studies have
compared the degree of the suppressive effects on the
afferent pathways of micturition between α1-adrenergic
receptor blockers and PDE inhibitors.
In this study, we investigated the effects of tamsulosin
and sildenafil and compared the degree of the suppressive
effects on the afferent pathways of micturition (the dorsal
horn of the L5 spinal cord, ventrolateral periaquaductal
gray (vlPAG) and PMC) between them.
Methods
Animals and experimental design
We used a total of 32 rats, aged 10 weeks, weighing
250±10 g (24 female SHRs and eight Wistar-Kyoto [WKY]
rats) in accordance with the animal care guidelines of the
National Institutes of Health (NIH) and the Korean
Academy of Medical Sciences (KAMS). We obtained
IRB (Institutional Review Board) approval for our study
(IRB# 1103–05). We randomly divided our experimental
animals into the following four groups:
(1)The WKY group (the control group) (n=8):
Water (1 mL) as the vehicle.
(2)The SHR group (n=8): Water (1 mL) as the vehicle.
(3)The SHR-Tam 0.01 mg/kg group (n=8): A 4-week
daily course of oral tamsulosin at a dose of 0.01 mg/kg
(4)The SHR-Sil 1 mg/kg group (n=8): A 4-week daily
course of oral sildenafil at a dose of 1 mg/kg.
Blood pressure monitoring and cystometry
Both the SHR and WKY rats were anesthetized with an
intraperitoneal injection of Zoletil 50® (10 mg/kg) (Vibac
Laboratories, Carros, France) composed of tiletaminehydrochloride and zolazepam hydrochloride. The rats
underwent implantation of a sterile polyethylene catheter
(PE50) into the femoral artery, connected to a pressure
transducer (Harvard Apparatus, Holliston, MA). Blood
pressure monitoring was done using Labscribe (iWork
System Inc., Dover, NH).
We performed cystometry as previously described [6].
Here, the cytometric parameters include the intercontrac-
tion interval, the basal pressure and duration of bladder
contraction, which were measured following an injection
of 0.5 mL of saline after the bladder was emptied. Changes
in the cystometric parameters were monitored by using
Labscribe (iWork System Inc., Dover, NH), and the basal
contractions defined as above 5 cmH2O were analyzed.
Histopathological examination and
immunohistochemistry
Following the cystometry, the rats were transcardially
perfused with 50 mM phosphate-buffered saline (PBS) and
then fixed using 4% paraformaldehyde in 100 mM sodium
phosphate buffer at pH 7.4. The brain was extracted,
postfixed in the same fixative overnight and transferred
to a 30% sucrose solution for cryoprotection. This was
followed by the preparation of serial coronal sections of
40 μm in thickness using a freezing microtome. The
vlPAG and the PMC were selected from the midbrain
region spanning from Bregma −7.64 to −8.00 mm and
from Bregma −9.68 to −9.80 mm, respectively. Then, the
dorsal horn of the L5 spinal cord was selected. In each
region, four sections were collected on average from
each rat.
To analyze the degree of the expression of c-Fos and
NGF in the afferent pathways of micturition, we performed
immunohistochemistry as previously described [6]. Coronal
sections of brain tissue were incubated overnight with
rabbit anti-c-Fos antibody and then treated with mouse
anti-NGF antibody (Santa Cruz Biotechnology Inc., Santa
Cruz, CA). This was followed by a 1-h incubation with
anti-rabbit secondary antibody followed by anti-mouse
secondary antibody (Vector Laboratories Inc., Burlingame,
CA). Subsequently, the tissue samples were incubated with
an avidin-biotin-peroxidase complex (Vector Laboratories)
at room temperature for 1 h. For immunohistochemistry,
the tissue samples were placed in a solution consisting
of 0.02% 3,3’-diaminobenzidine (DAB) tetrahydrochloride
(Sigma Chemical Co., St. Louis, MO) and 0.03% H2O2 in
50 mM Tris–HCl (pH 7.6). Then, the tissue samples were
rinsed with PBS three times and mounted onto gelatin-
coated slides. The slides were air-dried overnight at room
temperature, and the coverslips were mounted by using
Permount® (Fisher Scientific, Pittsburgh, PA).
The degree of the expression of c-Fos and NGF in the
afferent pathways of micturition was analyzed based on
the number of c-Fos- or NGF-positive cells using the
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(Media Cyberbetics Inc., Silver Spring, MD) installed in a
light microscope (Olympus, Tokyo, Japan). We expressed
the results as the number of cells/mm2 in each region.
Statistical analysis
Statistical analysis was performed using IBM SPSS (version
20.0; IBM Corp., Armonk, NY). All data are expressed
as the mean±SEM (SEM: standard error of the mean).
We also performed the one-way ANOVA and Duncan’s




The present results showed that the intercontraction
interval (ICI) significantly decreased in the SHR group as
compared with WKY group (P<0.05). In addition, the
basal pressure and duration of bladder contraction
were significantly higher and longer in the SHR group
(P<0.05). But they were significantly reduced in the
SHR-Tam 0.01 mg/kg group and the SHR-Sil 1 mg/kg
(P<0.05). These results indicate that the basal pressure
and duration of bladder contraction were significantly
reduced following the treatment with tamsulosin or
sildenafil. Moreover, Tam 0.01 mg/kg and Sil 1 mg/kg
significantly prolonged the ICI (P<0.05) (Figure 1).
The expression of c-Fos and NGF in the dorsal horn
of the L5 spinal cord
The degree of the expression of c-Fos and NGF was sig-
nificantly higher in the SHR group as compared with the
WKY group (P<0.05). But it was significantly reduced in
the SHR-Tam 0.01 mg/kg group and the SHR-Sil 1 mg/kg
group (P<0.05) (Figure 2). These results mean that the
enhancement of neuronal activities in the spinal cord
may be associated with the bladder overactivity, and Tam
0.01 mg/kg and Sil 1 mg/kg significantly suppressed these
activities.
The expression of c-Fos and NGF in the vlPAG
The expression of c-Fos and NGF was significantly
enhanced in the SHR group when compared with the
WKY group (P<0.05). On the other hand, it was signifi-
cantly reduced in the SHR-Tam 0.01 mg/kg group and the
SHR-Sil 1 mg/kg group (P<0.05) (Figure 3). These results
indicate that the increase in neuronal activities of the
vlPAG, a critical component of the micturition reflex, may
be involved in the bladder overactivity, and Tam 0.01 mg/
kg and Sil 1 mg/kg significantly suppressed these activities.
The expression of c-Fos and NGF in the PMC
The degree of the expression of c-Fos and NGF was
significantly higher in the SHR group as compared withthe WKY group (P<0.05). But it was significantly reduced
in the SHR-Tam 0.01 mg/kg group and the SHR-Sil 1 mg/kg
group (P<0.05) (Figure 4). From these results, Tam 0.01
mg/kg and Sil 1 mg/kg significantly suppressed the neur-
onal activities in the central micturirion region, the PMC.
Discussion
In an animal experimental model of hypertension using
SHRs, there were abnormal bladder functions, hyperactive
behavior (increased urinary frequency) and the increased
occurrence of non-voiding contractions that are suggestive
of detrusor overactivity [14]. Presumably, the OAB might
originate from the major abnormality of the central nervous
system, characterized by alterations in the noradrenergic
control of the micturition reflex [15].
According to de Groat and Yoshimura, the expression
of c-Fos in the spinal cord is an indicator of the involve-
ment of the spinal neurons in processing afferent signals
from the lower urinary tract via the spinal reflex pathway
[16]. Afferent pathways arising from the lower urinary
tract in rats project to the thoracolumbar (T12-L2) and
lumbosacral (L5-S1) regions of the spinal cord via the
hypogastric, pelvic and pudendal nerves [17]. It can there-
fore be inferred that the increased neuronal activity in the
lumbosacral region of the spinal cord might stimulate
the micturition centers in the brain. It is noteworthy
that the lateral and dorsal parts of the PAG receive the
afferent signals from the lumbosacral region of the spinal
cord [5]. Then, the afferent signals from the urinary
bladder are transmitted to the PAG via the neurons in the
lumbosacral region of the spinal cord when the bladder is
filled with urine. This is followed by the activation of the
cells sending a projection to the PMC of the PAG,
followed by the micturition [4,18]. In cases of OAB due to
the middle cerebral artery (MCA) occlusion, there is an
increase in the degree of the expression of c-Fos mRNA in
the pontine tegmental area [19]. The pontine tegmentum,
also known as the PMC, acts as a switch in the micturition
reflex pathway and it thereby controls the bladder capacity
and the pressure of bladder contraction [4,20]. With the
stimulation of the PMC by excitatory neurotransmitters,
bladder contraction is induced and its amplitude is
increased. In addition, the threshold bladder volume is
reduced [20]. Based on these reports, it can be inferred
that OAB symptoms might occur with the stimulation or
enhancement of neuronal activity in the PMC and PAG.
NGF modulates the neuronal function via the micturition
reflex pathway, and it plays a vital role in the pathogenesis
of bladder overactivity at the spinal level [21]. Its level is
elevated in the bladder, urethral tissue and urine collected
from patients with lower urinary tract symptoms (LUTS)
including OAB [8,22]. The OAB and hyperexcitability of
bladder afferent neurons are greatly dependent on an
NGF-induced decrease in A-type K+ current density as
Figure 1 (See legend on next page.)
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Figure 1 Changes in the cystometric parameters. (A) Blood pressure in the Wistar-Kyoto (WKY) rats and in the spontaneous hypertensive rats
(SHRs) (B) Representative cystometry curves (M represents the magnification of the cystometry curve). (C) Changes in the intercontraction
interval. (D) Changes in the basal contraction pressure. (E) Changes in the basal contraction time. *P < 0.05 compared with the WKY group. #P <
0.05 compared with the SHR group.
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[23]. Our results showed that the degree of NGF expression
in the dorsal horn of the L5 spinal cord, vlPAG and PMC
was significantly higher in the SHRs as compared with
the WKY rats. Taken together, it can be inferred that the
enhancement of NGF expression in the afferent pathways
of micturition might be induced by the OAB symptom.
Similarly to the degree of NGF expression in association
with the OAB, the degree of NGF expression in the
neuronal voiding centers (PMC and vlPAG) and the
dorsal horn of the L5 spinal cord was significantly in-
creased in an animal experimental model of stress urinary
incontinence [24].
With the activation of the α1-adrenergic receptor in the
bladder, the OAB symptoms are presented. It can therefore
be inferred that α1-adrenergic receptor antagonists might
be effective in improving the micturition functions [25]. It
has been reported that α1-adrenergic receptor antagonists,
including prazosin and tamsulosin, were effective inFigure 2 Changes in the degree of the expression of c-Fos and NGF i
photomicrographs of c-Fos- and NGF-positive cells. The scale bar represent
dorsal horn of the L5 spinal cord. (C) Changes in the degree of the express
compared with the WKY group. #P < 0.05 compared with the SHR group.significantly increasing the bladder capacity and lowering
the voiding frequency [26]. Moreover, α1-adrenergic recep-
tor antagonists act on the bladder wall and spinal cord and
thereby improve the bladder obstruction and the voiding
function [25]. But these reports failed to clarify the exact
mechanisms by which α1-adrenergic receptor antagonists
improve the bladder capacity and voiding functions.
According to Haga et al., the degree of c-Fos expression in
the spinal cord was significantly higher in the SHRs as
compared with the WKY rats [27]. These authors also
noted that prazosin had a significant effect in lowering the
degree of c-Fos expression in the spinal cord, thus sug-
gesting that α1-adrenergic receptor antagonist inhibits
the afferent signals from the lower urinary tract [27]. It has
been reported that α1-adrenergic receptor improved the
bladder storage function by suppressing the sensory C-fiber
afferent limb of the micturition reflex pathway [28].
It is well known that PDE-5 inhibitors improve the
LUTS, whose effects might be maximized during bladdern the dorsal horn of the L5 spinal cord. (A) Representative
s 100 μm. (B) Changes in the degree of the expression of c-Fos in the
ion of NGF in the dorsal horn of the L5 spinal cord. *P < 0.05
Figure 4 Changes in the degree of the expression of c-Fos and NGF in the PMC. (A) Representative photomicrographs of c-Fos- and
NGF-positive cells in each group. The scale bar represents 100 μm. (B) Changes in the degree of the expression of c-Fos in the PMC. (C) Changes
in the degree of the expression of NGF in the PMC. *P < 0.05 compared with the WKY group. #P < 0.05 compared with the SHR group.
Figure 3 Changes in the degree of the expression of c-Fos and NGF in the vlPAG. (A) Representative photomicrographs of c-Fos- and
NGF-positive cells. The scale bar represents 100 μm. (B) Changes in the degree of the expression of c-Fos in the vlPAG. (C) Changes in the
degree of the expression of NGF in the vlPAG. *P < 0.05 compared with the WKY group. #P < 0.05 compared with the SHR group.
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http://www.jbiomedsci.com/content/20/1/81filling [14,29,30]. Still, however, little is known about the
underlying mechanisms by which the PDE-5 inhibitors
have a treatment effect on LUTS or OAB. In addition,
no studies clarified their target sites [29]. According to
Caremel et al., the PDE-5 inhibitors inhibited the bladder
afferent neurons, thus possibly having an effect in improv-
ing the LUTS [30]. These authors reported that the nitric
oxide (NO)/cyclic guanosine monophosphate (cGMP)
signaling pathway is involved in the regulation of the
micturition reflex through an inhibitory effect on the
activity of afferent nerve fibers, thus providing the poten-
tial possibility of developing the treatment agents for OAB
based on the NO/cGMP pathway modulators.
There is a possibility that α1-adrenergic receptor antago-
nists and PDE inhibitors may improve the LUTS including
OAB [9]. Still, however, little is known about the underlying
mechanisms by which the α1-adrenergic receptor antago-
nists and PDE inhibitors modulate or affect urinary voiding
function in patients with OAB [12].
Based on our results, it can be concluded that α1-
adrenergic receptor antagonists and PDE-5 inhibitors may
have an effect in improving the voiding functions through
an inhibition of the neuronal activity in the dorsal horn of
the L5 spinal cord, vlPAG and PMC.
The limitations of the current study are as follows:
(1)We demonstrated that α1-adrenergic receptor
antagonist (tamsulosin) and PDE-5 inhibitor
(sildenafil) acted on the afferent pathways of
micturition and thereby suppressed their effects on
the micturition reflex. But we failed to clarify the
exact mechanisms that are involved in other
micturition regions such as the pelvis and pudendal
afferent and efferent nerves, the anterior cingulate
gyrus (ACG), medial preoptic nucleus (MPA) and
frontal cortex.
(2)We compared the suppressive effects on the
neuronal activity between the two drugs in a
monotherapy setting. Further animal experimental
studies are therefore warranted to compare the
suppressive effects on the neuronal activity between
α1-adrenergic receptor antagonists and PDE-5
inhibitors when concomitantly used.
(3)We failed to evaluate the dose-effect relationship of
sildenafil, which deserves further studies. To clarify
the dose-effect relationship, both drugs should be
treated at optimal dose. In our preliminary study, we
administered tamsulosin and sildenafil at varying
doses of 0.01 mg.kg/day, 0.1 mg/kg/day and 1 mg/
kg/day and 1 mg/kg/day, 5 mg/kg/day and 10 mg/
kg/day, respectively. Thus, we found that the degree
of efficacy of tamsulosin and sildenafil was highest
when administered at doses of 0.01 mg/kg/day and
1 mg/kg/day, respectively.Conclusions
In summary, we demonstrated that α1-adrenergic receptor
antagonists and PDE-5 inhibitors may have an effect in
improving the voiding functions through an inhibition of
the neuronal activity in the afferent pathways of mictur-
ition, such as the dorsal horn of the L5 spinal cord, vlPAG
and PMC. Moreover, tamsulosin was more effective in
alleviating the OAB symptoms by suppressing more
neuronal activity in the afferent pathways of micturition
as compared with sildenafil. But further prospective
clinical studies are warranted to establish their efficacy
in patients with OAB.
Abbreviations
ACG: Anterior cingulate gyrus; cGMP: Cyclic guanosine monophosphate;
DAB: 3,3′-diaminobenzidine; L5: 5th of lumbar vertebra; LUTS: Lower urinary
tract symptoms; MCA: Middle cerebral artery; MPA: Medial preoptic nucleus;
NGF: Nerve growth factor; NO: Nitric oxide; OAB: Overactive bladder;
PAG: Periaqueductal gray matter; PBS: Phosphate-buffered saline;
PDE: Phosphodiesterase; PDE-5: Phosphodiesterase-5; PMC: Pontine
micturition center; SHR: Spontaneously hypertensive rat; Sil: Sildenafil;
Tam: Tamsulosin; vlPAG: Ventrolateral periaquaductal gray; WKY: Wistar-kyoto.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
K-HK conceived and designed this study; S-EK drafted the manuscript and
acquired data; C-JK supervised this study and provided the critical revision of
the manuscript for important intellectual content; Il-GK and M-SS analyzed
and interpreted data; LH and In-YC provided the administrative, technical,
or material support. All authors read and approved the final manuscript.
Acknowledgment
This work was supported in part by the grants from the National Research
Foundation of Korea (NRF-2012R1A1A1013173).
Author details
1Department of Physiology, College of Medicine, Kyung Hee University, #1
Hoigi-dong, Dongdaemoon-gu, Seoul 130-701, Republic of Korea.
2Department of Urology, Gil Medical Center, Gachon University, #1198
Guwol-dong, Namdong-gu, Incheon 405-760, Republic of Korea.
Received: 25 June 2013 Accepted: 21 October 2013
Published: 25 October 2013
References
1. Parsons BA, Drake MJ: Animal models in overactive bladder research.
Handb Exp Pharmacol 2011, 202:15–43.
2. Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L: Impact of overactive
bladder symptoms on employment, social interactions and emotional
well-being in six European countries. BJU Int 2006, 97:96–100.
3. Marson L: Identification of central nervous system neurons that innervate
the bladder body, bladder base, or external urethral sphincter of female
rats: a transneuronal tracing study using pseudorabies virus.
J Comp Neurol 1997, 389:584–602.
4. Kavia RB, Dasgupta R, Fowler CJ: Functional imaging and the central
control of the bladder. J Comp Neurol 2005, 493:27–32.
5. Blok BF: Brain control of the lower urinary tract. Scand J Urol Nephrol Suppl
2002, 210:11–15.
6. Kim SE, Shin MS, Kim CJ, Park JH, Chung KJ, Jung H, Kim KH, Lee JH, Ko IG:
Effects of tamsulosin on urinary bladder function and neuronal activity
in the voiding centers of rats with cyclophosphamide-induced
overactive bladder. Int Neurourol J 2012, 16:13–22.
7. Dragunow M, Faull R: The use of c-fos as a metabolic marker in neuronal
pathway tracing. J Neurosci Methods 1989, 29:261–265.
8. Cruz F: Mechanisms involved in new therapies for overactive bladder.
Urology 2004, 63:65–73.
Kim et al. Journal of Biomedical Science 2013, 20:81 Page 8 of 8
http://www.jbiomedsci.com/content/20/1/819. Giuliano F: Lower urinary tract symptoms and sexual dysfunction: a
common approach. BJU Int 2008, 101(Suppl 3):22–26.
10. Montorsi F, Roehrborn C, Garcia-Penit J, Borre M, Roeleveld TA, Alimi JC,
Gagnier P, Wilson TH: The effects of dutasteride or tamsulosin alone and
in combination on storage and voiding symptoms in men with lower
urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH):
4-year data from the Combination of Avodart and Tamsulosin (CombAT)
study. BJU Int 2011, 107:1426–1431.
11. Giuliano F: Phosphodiesterase type 5 inhibitors improve male lower
urinary tract symptoms. Eur Urol 2008, 53:1121–1123.
12. Ückert S, Oelke M: Phosphodiesterase (PDE) inhibitors in the treatment of
lower urinary tract dysfunction. Br J Clin Pharmacol 2011, 72:197–204.
13. McVary KT, Siegel RL, Carlsson M: Sildenafil citrate improves erectile
function and lower urinary tract symptoms independent of baseline
body mass index or LUTS severity. Urology 2008, 72:575–579.
14. McMurray G, Casey JH, Naylor AM: Animal models in urological disease
and sexual dysfunction. Br J Pharmacol 2006, 147(Suppl 2):S62–S79.
15. Persson K, Pandita RK, Spitsbergen JM, Steers WD, Tuttle JB, Andersson KE:
Spinal and peripheral mechanisms contributing to hyperactive voiding
in spontaneously hypertensive rats. Am J Physiol 1998, 275:R1366–R1373.
16. de Groat WC, Yoshimura N: Changes in afferent activity after spinal cord
injury. Neurourol Urodyn 2010, 29:63–76.
17. Callsen-Cencic P, Mense S: Increased spinal expression of c-Fos following
stimulation of the lower urinary tract in chronic spinal cord-injured rats.
Histochem Cell Biol 1999, 112:63–72.
18. Holstege G: Micturition and the soul. J Comp Neurol 2005, 493:15–20.
19. Yotsuyanagi S, Yokoyama O, Komatsu K, Kodama K, Niikura S, Namiki M:
Expression of neural plasticity related gene in the pontine tegmental
area of rats with overactive bladder after cerebral infarction. J Urol 2001,
166:1148–1155.
20. Sugaya K, Nishijima S, Miyazato M, Ogawa Y: Central nervous control of
micturition and urine storage. J Smooth Muscle Res 2005, 41:117–132.
21. Ochodnicky P, Cruz CD, Yoshimura N, Michel MC: Nerve growth factor in
bladder dysfunction: contributing factor, biomarker, and therapeutic
target. Neurourol Urodyn 2011, 30:1227–1241.
22. Kuo HC, Liu HT, Chancellor MB: Urinary nerve growth factor is a better
biomarker than detrusor wall thickness for the assessment of overactive
bladder with incontinence. Neurourol Urodyn 2011, 29:482–487.
23. Yoshimura N, Bennett NE, Hayashi Y, Ogawa T, Nishizawa O, Chancellor MB,
de Groat WC, Seki S: Bladder overactivity and hyperexcitability of bladder
afferent neurons after intrathecal delivery of nerve growth factor in rats.
J Neurosci 2006, 26:10847–10855.
24. Ko IG, Kim SE, Kim BK, Shin MS, Kim CJ, Yim SJ, Bang YJ, Choi IH, Kim KH:
Swimming: effects on stress urinary incontinence and the expression of
nerve growth factor in rats following transabdominal urethrolysis.
Int Neurourol J 2011, 15:74–81.
25. Andersson KE: Overactive bladder-pharmacological aspects. Scand J Urol
Nephrol Suppl 2002, 210:72–81.
26. Jeong MS, Lee JG: The role of spinal and peripheral α1- and α2-
adrenoceptors on bladder activity induced by bladder distension in
anaesthetized rat. BJU Int 2000, 85:925–931.
27. Haga N, Aikawa K, Ishibashi K, Yanagida T, Nomiya M, Takahashi N, Shiomi
H, Oguro T, Ogawa S, Yamaguchi O: Long-term administration of prazosin
improves bladder storage function: results from a study in
spontaneously hypertensive rats. Int J Urol 2011, 18:785–791.
28. Yokoyama O: Pharmacological and genetic analysis of mechanisms
underlying detrusor overactivity in rats. Neurourol Urodyn 2010, 29:107–111.
29. Andersson KE: Prospective pharmacologic therapies for the overactive
bladder. Ther Adv Urol 2009, 1:71–83.
30. Caremel R, Oger-Roussel S, Behr-Roussel D, Grise P, Giuliano FA: Nitric
oxide/cyclic guanosine monophosphate signalling mediates an
inhibitory action on sensory pathways of the micturition reflex in the rat.
Eur Urol 2010, 58:616–625.
doi:10.1186/1423-0127-20-81
Cite this article as: Kim et al.: An animal study to compare the degree of
the suppressive effects on the afferent pathways of micturition
between tamsulosin and sildenafil. Journal of Biomedical Science
2013 20:81.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
